Tonix Pharmaceuticals Holding Corp (TNXP) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.64 is considered Undervalued compared with the five-year average of -1.19. The fair price of Tonix Pharmaceuticals Holding Corp (TNXP) is between 15.59 to 61.90 according to relative valuation method. Compared to the current price of 13.98 USD , Tonix Pharmaceuticals Holding Corp By Undervalued By 10.32%.

Relative Value

Fair Zone

15.59-61.90

Current Price：13.98

10.32%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Tonix Pharmaceuticals Holding Corp (TNXP) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Tonix Pharmaceuticals Holding Corp (TNXP) has a current Price-to-Book (P/B) ratio of 0.73. Compared to its 3-year average P/B ratio of 0.43, the current P/B ratio is approximately 68.47% higher. Relative to its 5-year average P/B ratio of 0.61, the current P/B ratio is about 18.98% higher. Tonix Pharmaceuticals Holding Corp (TNXP) has a Forward Free Cash Flow (FCF) yield of approximately -39.16%. Compared to its 3-year average FCF yield of -468.12%, the current FCF yield is approximately -91.63% lower. Relative to its 5-year average FCF yield of -362.05%, the current FCF yield is about -89.18% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for TNXP competitors is 2.04, providing a benchmark for relative valuation. Tonix Pharmaceuticals Holding Corp Corp (TNXP.O) exhibits a P/S ratio of 1.64, which is -19.94% above the industry average. Given its robust revenue growth of 16.58%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of TNXP increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of TNXP in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is TNXP currently overvalued or undervalued?

Tonix Pharmaceuticals Holding Corp (TNXP) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.64 is considered Undervalued compared with the five-year average of -1.19. The fair price of Tonix Pharmaceuticals Holding Corp (TNXP) is between 15.59 to 61.90 according to relative valuation method. Compared to the current price of 13.98 USD, Tonix Pharmaceuticals Holding Corp is Undervalued By 10.32%.

What is Tonix Pharmaceuticals Holding Corp (TNXP) fair value?

TNXP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Tonix Pharmaceuticals Holding Corp (TNXP) is between 15.59 to 61.90 according to relative valuation method.

How does TNXP's valuation metrics compare to the industry average?

The average P/S ratio for TNXP's competitors is 2.04, providing a benchmark for relative valuation. Tonix Pharmaceuticals Holding Corp Corp (TNXP) exhibits a P/S ratio of 1.64, which is -19.94% above the industry average. Given its robust revenue growth of 16.58%, this premium appears unsustainable.

What is the current P/B ratio for Tonix Pharmaceuticals Holding Corp (TNXP) as of Mar 03 2026?

As of Mar 03 2026, Tonix Pharmaceuticals Holding Corp (TNXP) has a P/B ratio of 0.73. This indicates that the market values TNXP at 0.73 times its book value.

What is the current FCF Yield for Tonix Pharmaceuticals Holding Corp (TNXP) as of Mar 03 2026?

As of Mar 03 2026, Tonix Pharmaceuticals Holding Corp (TNXP) has a FCF Yield of -39.16%. This means that for every dollar of Tonix Pharmaceuticals Holding Corp's market capitalization, the company generates -39.16 cents in free cash flow.

What is the current Forward P/E ratio for Tonix Pharmaceuticals Holding Corp (TNXP) as of Mar 03 2026?

As of Mar 03 2026, Tonix Pharmaceuticals Holding Corp (TNXP) has a Forward P/E ratio of -1.67. This means the market is willing to pay $-1.67 for every dollar of Tonix Pharmaceuticals Holding Corp's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Tonix Pharmaceuticals Holding Corp (TNXP) as of Mar 03 2026?

As of Mar 03 2026, Tonix Pharmaceuticals Holding Corp (TNXP) has a Forward P/S ratio of 1.64. This means the market is valuing TNXP at $1.64 for every dollar of expected revenue over the next 12 months.

TNXP Valuation